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Abstract
Background: Active smoking is an important risk factor for all-cause mortality and peripheral arterial disease (PAD).
In contrast, published studies on the associations with secondhand smoke (SHS) are limited. The aim of this study
was to examine the associations between SHS exposure and incident PAD, as well as mortality, among middle-
aged non-smokers.
Methods: We undertook a retrospective, cohort study using record linkage of the Scottish Health Surveys between
1998 and 2010 to hospital admissions and death certificates. Inclusion was restricted to participants aged >
45 years. Cox proportional hazard models were used to examine the association between SHS exposure and
incident PAD (hospital admission or death) and all-cause mortality, with adjustment for potential confounders.
Results: Of the 4045 confirmed non-smokers (self-reported non-smokers with salivary cotinine concentrations <
15 ng/mL), 1163 (28.8%) had either moderate or high exposure to SHS at baseline. In men, high exposure to SHS
(cotinine ≥2.7 ng/mL) was associated with increased risk of all-cause mortality (fully adjusted hazard ratio [HR] 1.54,
95% CI 1.07–2.22, p = 0.020) with evidence of a dose-relationship (p for trend = 0.004). In men, high exposure to SHS
was associated with increased risk of incident PAD over the first five years of follow-up (fully adjusted HR 4.29, 95%
CI 1.14–16.10, p = 0.031) but the association became non-significant over longer term follow-up.
Conclusions: SHS exposure was independently associated with all-cause mortality and may be associated with
PAD, but larger studies, or meta-analyses, are required to confirm the latter.
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Background
Secondhand smoke (SHS), also called ‘environmental to-
bacco smoke’ or ‘passive smoking’ or ‘involuntary smok-
ing’, is the inhalation of tobacco smoke by people other
than the active smoker. Worldwide, only 16% of the glo-
bal population is covered by smoke-free legislation pro-
tecting them from exposure to SHS in indoor public and
work places [1]. Legislation protecting against exposure
in private vehicles has been introduced in a small
number of countries but protects children only, and
non-smokers are not protected by legislation from ex-
posure in their own homes. In Scotland, six years after
the implementation of the smoke-free legislation ban-
ning smoking in enclosed public places, 17% of non-
smoking adults reported exposure to SHS in their home
or someone else’s home and 11% reported exposure out-
side of buildings (http://www.gov.scot/Publications/
2013/09/3684/8). Active smoking is a well-established
important and modifiable risk factor for all-cause mor-
tality and atherosclerotic diseases including peripheral
arterial disease (PAD) [2–4]. There is now substantial
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evidence that exposure to SHS also increases the risk of
premature death [5], coronary heart disease [6] and
stroke [7].
SHS is a mixture of air-diluted side-stream smoke
from the burning cigarette tip, and ‘mainstream’
smoke exhaled by the smoker. Side-stream smoke
contains higher concentrations of toxic gases and
fine, respirable particles (< 2.5 μm diameters) than
mainstream smoke [8–11]. Even short exposure to
SHS has been demonstrated to be associated with
impaired endothelium-dependent vasodilation in cor-
onary arteries in non-smokers; comparable to habit-
ual active smokers [12]. One hour exposure
increases the concentrations of 11-
dehydrothromoboxane B2 (11-DH-TXB2) and malon-
dialdehyde (MDA) to those observed in active
smokers [13]. A meta-analysis of 10 prospective co-
hort studies and 8 case-control studies, published in
1999, reported a pooled relative risk (RR) of 1.25
(95% CI 1.17–1.32) for coronary heart disease. There
were clear dose relationships with increasing dose
and duration of exposure to SHS from 1 to 19 ciga-
rettes per day (RR 1.23, 95% CI 1.13–1.34) to more
than 20 cigarettes per day (RR 1.31, 95% CI 1.21–
1.42) and from 1 to 9 years of exposure (RR 1.18,
95% CI 0.98–1.42), and 10–19 years of exposure (RR
1.31, 95% CI 1.11–1.55) to more than 20 years of ex-
posure (RR 1.29, 95% CI 1.16–1.43) [6]. A subse-
quent meta-analysis, published in 2011, of 4 cross-
sectional, 6 case-control, and 10 cohort studies,
showed an increased risk of stroke among non-
smokers who were exposed to SHS (RR 1.25 95% CI
1.12–1.38), with a dose relationship whereby the risk
increased from exposure to 5 (RR 1.16, 95% CI
1.06–1.27) to 40 (RR 1.56, 95% CI 1.25–1.96) ciga-
rettes per day [7].
In contrast, only five published cross-sectional
studies have examined the association between SHS
exposure and PAD [14–18]. Three of these studies
ascertained SHS exposure based on self-report [15,
17, 18] and the other two measured cotinine concen-
tration [14, 16]. Cotinine, a nicotine metabolite, is
an objective measure of tobacco exposure from all
sources [19]. Four of the studies demonstrated an
overall association [15–18], but one showed an asso-
ciation with PAD for only very high levels of expos-
ure to SHS (cotinine > 155 ng/mL) [14]. To date,
there have been no cohort studies published that
have examined the association between SHS expos-
ure in non-smokers and incident PAD. Therefore, we
linked individual-level data from the Scottish Health
Surveys to subsequent health records to examine
whether SHS exposure, measured by salivary cotinine
concentration, was an independent risk factor for
incident PAD, as well as all-cause mortality, among
non-smokers.
Methods
Data sources
The Scottish Health Surveys (SHeSs) are cross-sectional
studies designed to gain knowledge about the health of
the residents of private households across Scotland
(http://www.scotland.gov.uk/Topics/Statistics/Browse/
Health/scottish-health-survey). The Survey was first
conducted in 1995, with subsequent surveys undertaken
in 1998 and 2003 and then annually since 2008. The
Surveys use a multistage, stratified probability sampling
frame and different households were recruited into each
Survey. Household response rates were 81% in 1995,
76% in 1998, 68% in 2003, and 61%–64% between 2008
and 2010 [20]. The methodology has been described in
detail previously [16, 21]. Briefly, a two-stage process
was used: a face-to-face interview was conducted by
trained staff during which they collected information on
demographics (including age, sex, postcode of residence,
education, employment and income) and lifestyle (in-
cluding alcohol intake, physical activity and smoking sta-
tus) via computer assisted personal interviewing (CAPI),
followed by a visit by a nurse who collected measure-
ments (including height, weight and blood pressure)
using standard operating procedures. All individuals
aged ≥16 years were invited to provide a saliva sample
for cotinine assay and a blood sample for assays includ-
ing lipid concentrations. In each survey, over 90% of the
participants consented to passive follow-up via record
linkage to routine administrative data [20]. In Scotland,
the Information Services Division (ISD) of the National
Health Service (NHS) links, at an individual level, several
Scotland-wide databases including death certificates
(collated by the General Registrar Office) and admissions
to acute hospitals (Scottish Morbidity Record SMR01).
Inclusion criteria and definitions
In this study, we combined the 1998, 2003, 2008 and
2010 Surveys as they provided consistent information on
salivary cotinine and diagnosis of PAD at baseline. Our
study was restricted to participants aged > 45 years old
who classified themselves as non (never or ex) smokers
and whose salivary cotinine concentration was <
15.0 ng/ml [22]. Individuals with PAD at baseline and
those who reported taking nicotine replacement prod-
ucts were excluded. PAD at baseline was defined as
intermittent claudication ascertained using the Edin-
burgh Claudication Questionnaire [23]. SHS exposure
was categorised into low (cotinine < 0.7 ng/mL), moder-
ate (cotinine 0.7–2.6 ng/mL) and high (cotinine 2.7–
14.9 ng/mL) [16, 21]. In Scotland, area-based deprivation
is assessed using the Scottish Index of Multiple
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Deprivation (SIMD) which is derived from information
on income, employment, health, education, housing,
crime and access to services. The SIMD is used to derive
quintiles of deprivation, ranging from 1 (most deprived)
to 5 (least deprived) for the general Scottish population
(http://www.scotland.gov.gov.uk/Topics/Statistics/
SIMD). The study participants were categorised into
these quintiles based on their postcode of residence.
Body mass index (BMI) was classified as underweight /
normal weight (< 25 kg/m2), overweight (25–30 kg/m2)
and obese (≥30 kg/m2) [24]. Physically active was de-
fined as self-report of any kind of physical activity for at
least 3 h per week. Alcohol consumption was self-
reported as: never drinker, ex drinker, low-risk drinker
(men < 28 units/week; women < 21 units/week),
increasing-risk drinker (men < 50 units/week; women <
35 units/week) and high-risk drinker (men ≥50 units/
week; women ≥35 units/week). We used record linkage
to SMR01 records and death certificates to identify the
first hospital admission/death following the Survey in
which PAD was recorded as the primary or secondary
cause, defined as: International Classification of Disease,
Tenth Version (ICD-10) A48.0, I10.5, I73.9, I70.2, I70.9,
I74.3, I74.5, I79.2, R02; the International Classification of
Disease, Ninth Version (ICD-9) 250.7, 440.20, 440.21,
440.22, 440.23, 440.24, 440.29, 443.9, 443.81, 707.10,
785.4; or Office of Population Censuses and Surveys
Classification of Surgical Operations and Procedures
(OPCS) X09.3, X09.4, X09.5, X09.8, X09, X10.1, X10.4,
X10.8, X10.9, X11.1, X11.2, X11.8, X11.9, X12.1, L54.1,
L63.1. Audits have shown that the SMR data are around
99% complete and over 90% accurate [20]. The linked
data provided follow-up information to 31 December
2011.
Statistical analyses
Differences in baseline characteristics by SHS exposure
were summarised using chi-square tests for categorical
variables and chi-square tests for trend for ordinal vari-
ables. Incident PAD cases were ascertained based on
hospital admissions or deaths due to PAD. We used
person-time incidence rate which can account for partic-
ipants who entered the study at different times and
those who were lost to follow-up or died during the
study period [25]. The numerator was the number of in-
cident PAD cases and the denominator was the sum of
all of the person-years of observation for all study partic-
ipants. Tests of Cox proportional-hazards assumptions
were performed using Stata estat phtest [26]. Separate
Cox proportional hazard models were developed to
examine the association between levels of SHS exposure
and two separate outcomes: incident PAD (hospital ad-
mission or death) and all-cause mortality. We ran sev-
eral models with increasing levels of statistical
adjustment for potential confounders: unadjusted, par-
tially adjusted (age and sex) and fully adjusted (partially
adjusted model plus deprivation quintile, BMI category,
physical activity, alcohol consumption and survey year)
using cotinine < 0.7 ng/mL as the reference category
[16]. Statistical interactions with covariates were tested
using likelihood ratio tests [27, 28]. Statistical signifi-
cance was defined as a two-sided p-value < 0.05 for both
main effects and interactions. The probability of survival
to a given time point was estimated using the Kaplan-
Meier method. The cumulative hazard of PAD over time
was estimated using the Nelson-Aalen method. The log-
rank test was used to assess if the curves representing
different groups, in this case, different SHS exposure
groups, differed significantly. All statistical analyses were
performed using Stata 12.0 (Stata Corporation, College
Station, Texas, USA).
Results
Of the 41,664 participants in the four Scottish Health
Surveys, 37,967 (91.1%) had consented to passive follow-
up via record linkage to routine administrative data.
Among these, 17,128 (45.1%) were aged > 45 years. Of
these, 83 were excluded because they were on nicotine
replacement therapy (NRT). Of the remainder, 10,817
participants completed the Edinburgh Claudication
Questionnaire and were free of intermittent claudication.
Of these participants, 6772 were excluded because: 1246
reported being current smokers, 188 reported being
non-smokers but had a cotinine concentration ≥ 15 ng/
mL, and 5338 did not provide a saliva sample. Therefore,
4045 participants comprised this study population
(Fig. 1).
Fig. 1 Flow diagram of participant inclusion and exclusion
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Of these, 2216 (54.8%) classified themselves as never
smokers and 1829 (45.2%) as ex-smokers. Among ex-
smokers, 1774 (97.0%) had quit smoking at least one
year prior to the survey and 1620 (88.6%) at least five
years. Overall, 1163 (28.8%) participants had either mod-
erate or high exposure to SHS at baseline. The mean age
at recruitment was 61 (SD 10) years and there was a
total of 29,040 person years of follow-up (mean follow-
up 9 years). Over the follow-up period there were 568
deaths, none of which were coded as due to PAD, and
64 people were hospitalised for PAD. All-cause mortality
rates were 18.1% (95% CI 16.3%–20.0%) per 1000
person-years, 23.0% (95% CI 19.5%–27.0%) per 1000
person-years, and 25.3% (95% CI 19.7%–32.6%) per 1000
person-years among participants with no or low, moder-
ate and high SHS exposure respectively. PAD incidence
rates were 2.0% (95% CI 1.5%–2.7%) per 1000 person-
years in participants with no or low SHS exposure, 2.5%
(95% CI 1.5%–4.1%) per 1000 person-years in partici-
pants with moderate exposure, and 3.3% (95% CI 1.7%–
6.2%) per 1000 person-years in participants with high
exposure. Among male participants, PAD incidence rate
was 5.7% (95% CI 2.7%–12.0%) among those with high
exposure, compared with 1.5% (95% CI 0.6%–3.7%)
among those with moderate exposure and 1.8% (95% CI
1.1%–3.0%) among those with low or no exposure.
Compared with the no or low SHS exposure group,
participants with high exposure were older, and more
likely to be male, obese and socioeconomically deprived;
they drank more alcohol and were less physically active
(Table 1). There was a statistically significant association
between baseline exposure to SHS and all-cause mortal-
ity overall (Table 2, Fig. 2) and among the male sub-
group of participants (Table 2). Figure 2 illustrates the
difference across SHS exposure groups in terms of prob-
ability of survival (log-rank test p = 0.013). In the univar-
iate and multivariate Cox proportional hazard models,
there was a significant overall association between SHS
exposure and mortality (Table 2). Among men, there
was a clear, and significant, dose relationship that per-
sisted in the age-adjusted and fully adjusted models
(Table 2).
In relation to incident PAD, the association with base-
line exposure to SHS did not reach statistical signifi-
cance overall (Table 2). There was no difference across
SHS exposure groups overall (Fig. 3: log-rank test p =
0.386). However, there was a significant interaction with
sex (p = 0.025). Male participants with high exposure to
SHS were significantly more likely to experience PAD
events in the unadjusted and age-adjusted models (Table
2, Fig. 4). Figure 4 illustrates the difference in the cumu-
lative incidence of PAD across SHS exposure groups
(log-rank test p = 0.026). After adjustment for other po-
tential confounders, the hazard ratio was attenuated and
no longer reached statistically significant. Among female
non-smokers, there were no significant associations be-
tween baseline exposure to SHS and either all-cause
mortality or PAD hospitalisations. There were no signifi-
cant interactions with other covariates. The proportional
hazards assumptions were met (global test: all p > 0.05)
in all of the models except for the adjusted models for
all-cause mortality in the female only sub-group (global
test: p = 0.018 for partially adjusted model and p < 0.001
for fully adjusted model). The numbers of participants
were too small to run subgroup piecewise analysis strati-
fied by the other covariates.
Among male non-smokers, the association between
high SHS exposure (cotinine ≥2.7 ng/mL) and incident
PAD was significant over the first five years of follow-up
even in the fully adjusted model (unadjusted HR 5.04,
95% CI 1.42–17.80, p = 0.012; fully adjusted HR 4.29,
95% CI 1.14–16.10, p = 0.031) but the association was
weaker and became non-significant for events that oc-
curred more than five years from baseline (unadjusted
HR 1.83, 95% CI 0.50–6.75, p = 0.359; fully adjusted HR
1.34, 95% CI 0.28–6.54, p = 0.715).
Discussion
Our study demonstrated that, among non-smokers, ex-
posure to SHS was associated with an increased risk of
all-cause mortality, with evidence of a dose relationship.
Among male non-smokers, there was also evidence that
high exposure to SHS (cotinine ≥2.7 ng/mL) was associ-
ated with increased risk of incident PAD over the subse-
quent five years.
Our finding of an independent association between
SHS exposure and all-cause mortality is consistent with
previous findings. Retrospective data from 192 countries
were used to assess the global burden of disease and es-
timated that around 603,000 premature deaths in 2004
were attributable to SHS, with ischaemic heart disease
making the largest contribution to SHS-related deaths
[5].
PAD often co-exists with coronary heart disease and
stroke in the same individuals [29]. They share many
common risk factors including active cigarette smoking
[2, 29]. Two meta-analyses have shown that exposure to
SHS is associated with increased risk of coronary heart
disease and stroke respectively [6, 7]. In contrast, so far,
only five published individual studies have assessed SHS
exposure and PAD, and all were cross-sectional in de-
sign [14–18]. Four of these reported significant associa-
tions [15–18]. One study was conducted among 1209
Chinese women aged ≥60 years who had never smoked.
The study reported a significant overall association with
PAD whether ascertained from the WHO Rose Ques-
tionnaire (adjusted OR 1.87, 95% CI 1.30–2.68, p =
0.001), ankle-brachial pressure index (ABPI) < 0.90
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(adjusted OR 1.47, 95% CI 1.07–2.03, p = 0.018), or by
either (adjusted OR 1.67, 95% CI 1.23–2.16, p < 0.001).
There was evidence of a dose-response relationship in
relation to both the number of cigarettes the participants
were exposed to each day and the daily duration of
exposure [15]. This was followed by a study which ana-
lysed data on 5653 non-smokers aged > 40 years in the
USA using data from the National Health and Nutrition
Examination Surveys. When non-smokers were dichoto-
mised into those exposed to SHS (serum cotinine 0.05–
Table 1 Baseline characteristics of non-smokers by cotinine concentrations
Cotinine (ng/mL)
0–0.6 0.7–2.6 2.7–14.9
N = 2882 N = 850 N = 313 P valuesa
N (%) N (%) N (%)
Age (years)
45–59 1338 (46.4) 406 (47.8) 124 (39.6) 0.042
≥ 60 1544 (53.6) 444 (52.2) 189 (60.4)
Sex
Male 1250 (43.4) 423 (49.8) 167 (53.4) < 0.001
Female 1632 (56.6) 427 (50.2) 146 (46.6)
Deprivation quintile
1(most deprived) 315 (10.9) 137 (16.1) 75 (24.0) < 0.001
2 479 (16.7) 190 (22.4) 82 (26.2)
3 622 (21.6) 202 (23.8) 55 (17.6)
4 697 (24.2) 153 (18.0) 50 (16.0)
5(least deprived) 644 (22.3) 141 (16.6) 40 (12.8)
Missing 125 27 11
Body mass index (kg/m2)
< 25.0 670 (23.2) 151 (17.8) 46 (14.7) < 0.001
25.0–29.9 1181 (41.0) 347 (40.8) 122 (39.1)
≥ 30 757 (26.3) 272 (32.0) 122 (39.0)
Missing 274 80 23
Physically active
No 1441 (50.0) 450 (52.9) 177 (56.5) < 0.001
Yes 1251 (43.4) 332 (39.1) 101 (32.3)
Missing 190 68 35
Alcohol consumption
Never drinker 237 (8.2) 51 (6.0) 25 (8.0) < 0.001
Ex drinker 129 (4.5) 43 (5.1) 23 (7.3)
Low-risk drinker 2300 (79.8) 655 (77.1) 211 (67.4)
Increasing-risk drinker 163 (5.7) 66 (7.8) 33 (10.5)
High-risk drinker 51 (1.8) 34 (4.0) 19 (6.1)
Missing 2 1 2
Smoking status
Never smokers 1631 (56.6) 434 (51.1) 151 (48.2) < 0.000b
Ex-smokers stopped smoking ≥5 years 1149 (39.9) 341 (40.1) 130 (41.5)
Ex-smokers stopped smoking ≥1 year 1225 (42.5) 398 (46.8) 151 (48.2)
Ex-smokers stopped smoking < 1 year 22 (0.8) 16 (1.9) 11 (3.5)
Missing 4 2 0
aχ2 test
bχ2 test for smoking status (never smokers, ex-smokers stop ≥1 year, ex-smokers stop < 1 year)
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10 ng/mL) and those not (cotinine < 0.05 ng/mL), there
was no association with PAD, defined by ABPI. However,
when SHS exposure was categorised into a larger num-
ber of sub-groups, the investigators reported a
significant association with cotinine concentrations >
155 ng/mL and suggested a possible threshold effect
[14]. Prior to this present study, we previously con-
ducted two cross-sectional studies on the Scottish
Table 2 Cox proportional hazard models of the association between secondhand smoke exposure, peripheral arterial disease and
all-cause mortality
Cotinine
(ng/mL)
Number of events/ number
of participants
Unadjusted Partially
adjusted†
Fully adjusted‡
HR
(95%CI)
P
value
P value for
trend
HR
(95%CI)
P
value
P value for
trend
HR
(95%CI)
P
value
P value for
trend
PAD incidence
All non-
smokers1
0–0.6* 40/2882 1.00 – 0.172 1.00 – 0.140 1.00 – 0.382
0.7–2.6 16/850 1.26
(0.71–
2.25)
0.437 1.30
(0.73–
2.33)
0.372 1.15
(0.64–
2.06)
0.648
2.7–14.9 8/313 1.64
(0.77–
3.49)
0.203 1.66
(0.77–
3.51)
0.184 1.38
(0.65–
2.95)
0.400
Male non-
smokers1
0–0.6* 16/1250 1.00 – 0.100 1.00 – 0.084 1.00 – 0.280
0.7–2.6 5/423 0.82
(0.30–
2.24)
0.702 0.91
(0.33–
2.49)
0.848 0.76
(0.28–
2.07)
0.595
2.7–14.9 7/167 2.89
(1.18–
7.10)
0.021 2.82
(1.14–
6.96)
0.024 2.10
(0.78–
5.65)
0.141
Female non-
smokers1
0–0.6* 24/1632 1.00 – – 1.00 – – 1.00 – –
0.7–2.6 11/427 1.66
(0.81–
3.38)
0.165 1.65
(0.81–
3.37)
0.168 1.51
(0.73–
3.15)
0.266
2.7–14.9 1/146 ** ** ** ** ** **
All-cause mortality
All non-
smokers1
0–0.6* 362/2882 1.00 – 0.004 1.00 – 0.001 1.00 – 0.043
0.7–2.6 145/850 1.25
(1.03–
1.52)
0.022 1.34
(1.10–
1.63)
0.003 1.24
(1.02–
1.51)
0.034
2.7–14.9 61/313 1.30
(1.04–
1.79)
0.024 1.42
(1.09–
1.86)
0.011 1.21
(0.91–
1.61)
0.194
Male non-
smokers1
0–0.6* 178/1250 1.00 – 0.006 1.00 – 0.001 1.00 – 0.004
0.7–2.6 85/423 1.26
(0.98–
1.63)
0.077 1.47
(1.13–
1.92)
0.004 1.40
(1.07–
1.83)
0.014
2.7–14.9 41/167 1.52
(1.09–
2.13)
0.014 1.54
(1.08–
2.18)
0.016 1.54
(1.07–
2.22)
0.020
Female non-
smokers2
0–0.6* 184/1632 1.00 – 0.475 1.00 – 0.504 1.00 – 0.523
0.7–2.6 60/427 1.14
(0.85–
1.53)
0.380 1.14
(0.85–
1.53)
0.368 1.03
(0.76–
1.40)
0.836
2.7–14.9 20/146 1.07
(0.68–
1.70)
0.764 1.05
(0.67–
1.65)
0.828 0.80
(0.51–
1.27)
0.344
HR hazard ratio, CI confidence interval, PAD peripheral arterial disease
*reference; ** only one participant; † adjusted for age and sex for all non-smokers, adjusted for age for male or female non-smokers; ‡ partially adjusted plus
deprivation quintile, body mass index, physical activity, alcohol consumption and survey year
1Test of proportional-hazards assumption all p ≥ 0.050
2Test of proportional-hazards assumption all p < 0.050
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general population [16, 17] and one cross-sectional
study on the Chinese general population [18]. Analysis
of baseline data from the Scottish Family Health Study
on 5686 never smokers aged ≥18 years demonstrated an
overall association between self-reported level of SHS
exposure and PAD defined by ABPI < 0.90 (adjusted OR
5.56, 95% CI 1.82–17.06, p = 0.003 for total exposure
≥40 h per week) [17]. The second study used baseline
data from the Scottish Health Survey on 4231 non-
smokers (self-reported non-smokers with salivary cotin-
ine < 15 ng/mL) aged > 45 years. Participants with cotin-
ine concentrations ≥2.7 ng/mL were significantly more
likely to have intermittent claudication ascertained using
the Edinburgh Claudication Questionnaire (adjusted OR
1.76, 95% CI 1.04–3.00, p = 0.040), compared to those
with no or low SHS exposure (cotinine < 0.7 ng/mL).
There was evidence of a dose-relationship across cotin-
ine concentrations rather than a threshold effect, with
differences achieving statistical significance above cotin-
ine concentrations of only 2.7 ng/mL [16]. The third
study used baseline data from the Guangzhou Biobank
Cohort Study: Cardiovascular Disease Sub-cohort Study
on 1507 non-smokers who aged ≥50 years. Exposure to
SHS at home of ≥25 h per week was associated with
PAD defined by ABPI < 0.90 (adjusted OR 7.86, 95% CI
2.00–30.95, p = 0.003), with evidence of a dose-response
relationship [18]. However, prior to the current study,
there have been no published studies of the association
between SHS and incident PAD. In fact, very few studies
on the general population have collected information on
both SHS exposure and PAD.
The previous cross-sectional studies were unable to
exclude the possibility of reverse causation. By using a
cohort design, we were able to demonstrate a temporal
relationship between SHS exposure and subsequent de-
velopment of PAD. We observed statistical differences
across no, low and high SHS exposure groups in terms
of the probability of survival using a Kaplan-Meier plot
and in terms of cumulative hazard of incident PAD
using a Nelson-Aalen plot. Using Cox proportional haz-
ard regression analyses, we demonstrated a higher haz-
ard of death among participants with SHS exposure,
compared with those without. However, the higher haz-
ard of incident PAD reached statistical significance only
among male participants with high SHS exposure. Our
cohort study used record linkage of a pan-Scotland rep-
resentative survey of the general population. Over 90%
of the participants in the baseline surveys consented to
passive follow-up via record linkage to routine adminis-
trative data on hospitalisation and death certification
[20]. Researchers have no control over the completeness
and accuracy of routine administrative data; however,
the SMR02 dataset is subject to regular quality assurance
checks (http://www.isdscotland.org/Products-and-Ser-
vices/Data-Quality/).
The Scottish Health Surveys measured SHS exposure
objectively using salivary cotinine concentration. This
enabled us to exclude smoking deceivers by applying a
maximum cut-off of 15 ng/mL for salivary cotinine con-
centrations; as validated by the Society for Research on
Nicotine and Tobacco [22]. In order to maximise
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statistical power, we included ex-smokers as well as
never smokers but the majority of ex-smokers (88.6%)
had quit smoking at least five years prior to participating
in the Survey. Each Survey collected baseline data on
demographics and lifestyle. Therefore, in our statistical
models, we were able to adjust for potential confounders
such as age, sex, socioeconomic deprivation quintiles,
BMI, physical activity and alcohol consumption. We
were able to study two outcomes, incident PAD and all-
cause mortality, the same cohort. Exposure to SHS is as-
sociated with diabetes [30–32], dyslipidaemia [33–35]
and raised blood pressure [35–37], and some previous
studies have adjusted for these covariates [14, 15]. These
conditions are likely to lie on the causal pathway and,
thus, are more likely to be mediators than confounders.
Therefore, we did not include them in the model as this
would have biased the results towards the null [38].
In line with previous studies on PAD, we only included
participants who were > 45 years of age [16, 39]. The
Surveys did not use an objective measure, such as ABPI,
to ascertain prevalent PAD; however, PAD at baseline
was defined via a widely used and well-validated ques-
tionnaire, the Edinburgh Claudication Questionnaire.
Therefore, we were able to exclude participants with
symptomatic PAD at baseline but not those with asymp-
tomatic disease. Since ex-smokers are more likely to
have developed intermittent claudication than never
smokers [2]; they will have been disproportionately ex-
cluded. If the magnitude of the association between SHS
and incident PAD varies by smoking status; this could
potentially have introduced bias. Previous studies have
suggested that the magnitude of the association with ac-
tive smoking is greater for PAD than coronary heart dis-
ease [29, 40, 41]. Therefore, it might be hypothesised
that this should also be true of SHS exposure. However,
it would be inappropriate to compare our results directly
with similar studies conducted on coronary heart disease
since our ascertainment of incident PAD was limited to
severe cases warranting hospitalisation.
The main limitation of this study was that the ascer-
tainment of incident PAD was restricted to those partici-
pants who developed PAD of sufficient severity to
warrant hospitalisation or predispose to death. The true
incidence of PAD is likely to be higher than that re-
ported in our study, and the association demonstrated
between SHS exposure and severe PAD may reflect the
combination of an association with overall incidence and
an association with disease progression.
Another limitation of our study was the lack of serial
information on smoking status and SHS exposure.
Among men, the association between SHS exposure at
baseline and PAD was significant for incident events that
occurred within five years of baseline data collection but
reduced in magnitude and became statistically non-
significant thereafter. The latter is likely to reflect meas-
urement error due to baseline SHS exposure no longer
being a good measure of current SHS exposure; and the
former may be a better estimate of the true magnitude
of association between SHS exposure and PAD.
Conclusion
Our study corroborates previous findings of an associ-
ation between SHS exposure and all-cause mortality and
is the first to demonstrate an association between SHS
exposure and incident PAD. Our findings, in relation to
PAD, only reached statistical significance in men and
over the first five years of follow-up. Larger studies with
serial measurements of exposure are required to prop-
erly evaluate the association in women and over longer
follow-up. In comparison with coronary heart disease
and stroke, recording of PAD has been neglected in large
cohort studies; and future studies should address this
deficit. Our findings add weight to the existing evidence
that SHS is a threat to public health and measures
should be taken to protect the general population from
exposure.
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